The aim of study is to examine the relationship between lipid subfractions, inflammation and structural-functional properties of the arterial wall in patients with premature coronary heart disease, to study genetic polymorphisms that determine lipid subfractions concentration on the functional and morphological properties of the arterial vascular wall in patients with early coronary heart disease, to study the effect of alirocumab and evolocumab on lipid subfractions, inflammation and structural-functional properties of arterial wall in patients with early coronary atherosclerosis and to study the influence of NOS-3 gene expression on the functional and morphological properties of the arterial vascular wall in the same patients. Impaired blood fat metabolism and chronic inflammation are intertwined as possible causes of atherosclerosis. Lipoprotein (a) (Lp (a)) is an important risk factor for coronary heart disease and a prognostic predictor in patients after myocardial infarction, but recent research suggests that subtilisin-kexin convertase type 9 (PCSK9) inhibitors are the only drugs that significantly reduce serum Lp (a) concentration. However, there are no data on the relationship between Lp (a) values and polymorphisms for Lp (a), indicators of inflammation and impaired arterial function, and response to treatment with various PCSK9 inhibitors in patients with early coronary heart disease.

NCT04613167

Conditions

1. Acute Coronary Syndrome
2. Premature Coronary Heart Disease
3. Lipoproteinemia
4. Inflammation
5. Genetic Polymorphisms

Interventions

1. Drug: Alirocumab
2. Drug: Evolocumab
3. Drug: Control group

MeSH:Premature Birth Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases Acute Coronary Syndrome Inflammation

HPO:Coronary artery atherosclerosis Myocardial infarction Premature birth

Among them, rs2070744, rs3918226 and rs1799983 single nucleotide polymorphisms (SNP) are important.